^
Association details:
Biomarker:KRAS A59T
Cancer:Colorectal Cancer
Drug:Vectibix (panitumumab) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab

Excerpt:
...a remarkable clinical, radiographic, and CEA biomarker response of a patient with metastatic CRC harboring the A59T missense mutation of KRAS treated for 8 months with panitumumab and a FOLFIRI backbone.
Secondary therapy:
FOLFIRI